PROTAC Activity Assay Services

Name: PROTAC Activity Assay
Brand: BOC Sciences

PROTAC activity assay is the cornerstone of targeted protein degrader development, providing the quantitative and mechanistic data needed to advance candidates from initial hits to optimized leads. Unlike traditional small-molecule inhibitors where binding affinity often predicts functional outcome, PROTACs operate through a catalytic degradation mechanism that requires ternary complex formation, ubiquitin transfer, and proteasome engagement. This complexity demands specialized assay strategies that capture not only target engagement but also the full degradation trajectory. BOC Sciences delivers comprehensive PROTAC in vitro evaluation services centered on activity assay design, execution, and interpretation. Our services span quantitative degradation profiling, binding confirmation, ternary complex analysis, ubiquitination verification, and cell-based functional evaluation to help research teams understand how their degraders perform across diverse biological contexts and make informed optimization decisions.

Request a Consultation Explore Services

Services

BOC Sciences PROTAC Activity Assay Services Capabilities

Quantitative Degradation Activity Profiling We measure PROTAC-induced target degradation using quantitative immunoassay and imaging-based approaches to determine DC₅₀, D_max, and degradation efficiency. These activity data enable direct comparison between analogs and support structure-degradation relationship analysis. Our degradation ability assay services connect activity profiling with mechanistic insight.
Target Engagement and Binary Binding Confirmation Before degradation can occur, the PROTAC must engage both the target protein and the E3 ligase. We perform binding affinity measurement to confirm binary target engagement, assess cooperativity in ternary complex formation, and determine whether observed cellular activity aligns with binding strength. This helps distinguish binding-driven from event-driven degradation behaviors.
Ternary Complex Formation and Cooperativity Analysis The ternary complex is the functional intermediate that determines PROTAC efficacy and selectivity. Our PROTAC ternary complex assay services evaluate complex stability, formation kinetics, hook-effect behavior, and the influence of linker length and E3 ligase choice. Understanding ternary complex dynamics is essential for rational PROTAC optimization.
Ubiquitination and Proteasome-Dependence Verification True PROTAC activity requires ubiquitin transfer followed by proteasomal degradation. We verify this mechanism through E3 ubiquitin ligase activity assay platforms and proteasome inhibitor controls, confirmed through protein ubiquitination services. This step eliminates false positives from transcriptional suppression, translational blockade, or off-target effects.
Cell-Based Functional Activity Evaluation Beyond target protein loss, we assess downstream pathway modulation, phenotypic changes, and functional responses linked to degradation. This includes signaling cascade analysis, proliferation impact, and biomarker modulation in disease-relevant cellular models. Functional readouts help bridge the gap between target engagement and biological consequence.
Comparative Activity Screening for PROTAC Analogs Lead optimization often generates series of analogs with varying linkers, E3 ligands, and warhead modifications. We design parallel activity assays that compare degradation potency, efficacy, kinetics, and selectivity across analog sets under matched conditions, enabling structure-activity relationship interpretation and candidate prioritization.

Readouts

Key Activity Readouts for PROTAC Candidate Evaluation

DC₅₀, D_max, and Degradation Efficiency

DC₅₀ represents the PROTAC concentration at which 50% target degradation is achieved, while D_max indicates the maximal degradation depth. Together with calculated degradation efficiency, these parameters allow precise ranking of candidates and comparison across cell models.

Time-Dependent Degradation Kinetics

PROTACs operate catalytically, meaning degradation onset, maximal depth, and recovery dynamics are time-sensitive. We capture time-course profiles to determine degradation speed, duration, and target recovery patterns that inform dosing strategy and compound stability.

Hook Effect Identification and Concentration-Response Interpretation

At supraphysiological concentrations, binary target-ligase competition can disrupt ternary complexes and reduce degradation. Detecting this hook effect is critical for correct concentration-response interpretation and avoiding false-negative conclusions about compound activity.

Target Protein Recovery and Re-Synthesis Analysis

Measuring how quickly degraded targets re-accumulate after PROTAC washout reveals the balance between degradation rate and protein re-synthesis. This readout distinguishes long-acting from short-acting degraders and informs duration-of-action estimates.

Activity-to-Cytotoxicity Window Assessment

A therapeutically useful PROTAC should degrade its target well below concentrations that cause non-specific cellular toxicity. We determine this separation window by measuring degradation and viability endpoints under identical conditions to support safety-margin evaluation.

Structure-Activity and Structure-Degradation Relationship Mapping

By correlating linker length, polarity, flexibility, E3 ligase choice, and warhead modifications with activity parameters, we help clients identify which structural elements drive degradation potency and which can be optimized for improved developability.

Need Accurate Activity Data to Advance Your PROTAC Program?

From quantitative degradation profiling to ternary complex analysis, we deliver the activity data you need for confident lead optimization.

Get a Quote

Platforms

Technical Platforms Supporting PROTAC Activity Assays

Western Blot and Capillary Immunoassay Platforms Western blot remains a foundational technique for PROTAC activity assessment, offering target-specific detection and semi-quantitative degradation measurement. We complement this with automated capillary immunoassay systems that reduce sample volume, improve reproducibility, and enable higher throughput for analog screening and time-course studies. Target protein quantification with validated antibodies Time-course and dose-response degradation curves Loading control normalization and quantification software
Immunofluorescence and High-Content Imaging Assays High-content imaging enables single-cell resolution of PROTAC-induced target degradation, allowing analysis of cell-to-cell variability, subcellular localization changes, and target loss kinetics within intact cellular environments. Immunofluorescence supports target visualization, colocalization studies, and morphology assessment. Single-cell degradation quantification Subcellular target distribution and trafficking analysis Multiparametric morphology and pathway marker profiling
Flow Cytometry-Based Protein Degradation Analysis Flow cytometry provides rapid, quantitative assessment of target protein levels across large cell populations. This platform is especially valuable for examining PROTAC activity in heterogeneous samples, comparing responses across cell types, and screening multiple conditions in a single experiment. Population-level degradation quantification Multi-color panel for target and pathway co-analysis Cell-type-specific activity in mixed populations
ELISA and Plate-Based Quantitative Detection Plate-based assays offer high-throughput-compatible quantification of PROTAC-mediated target degradation. Our capabilities include target-specific ELISA formats, complemented by TR-FRET in vitro ubiquitylation assay and ELISA-based in vitro ubiquitylation assay systems that link ubiquitin transfer activity with degradation outcomes. Sandwich and competitive ELISA for target quantification Ubiquitination detection and proteasome-dependence confirmation 96- and 384-well format for screening scalability
Mass Spectrometry-Assisted Target Protein Analysis Mass spectrometry enables unbiased, highly specific detection of target protein abundance changes without antibody dependence. This platform supports targeted proteomics for precise target quantification and global proteomics for off-target degradation assessment alongside primary activity evaluation. Targeted proteomics for precise target-level quantification Global proteome profiling for selectivity assessment Protein modification and ubiquitination site mapping
Reporter-Free Cellular Assay Development For targets where antibody-based detection is limited, we develop reporter-free cellular assays using endogenous protein detection, proximity-based methods, or functional pathway readouts. These customized formats ensure that difficult-to-measure targets can still be evaluated with quantitative precision. Endogenous target detection without genetic modification Pathway and functional surrogate readouts Custom assay development for novel targets

Customization

Customized Assay Design for Different PROTAC Project Needs

Early Hit Screening and Activity Ranking For projects at the hit-to-lead stage, we design rapid PROTAC high-throughput screening formats that rank compounds by degradation activity using minimal material. Single-point and multi-point screening strategies are tailored to compound availability and information needs.
Lead Optimization and Analog Comparison During lead optimization, subtle structural changes can significantly affect degradation activity. We execute detailed dose-response, kinetic, and mechanistic assays across analog series to guide decisions on linker modification, E3 ligase switching, and warhead refinement with quantitative confidence.
Difficult Target and Low-Abundance Protein Assay Development Targets with low endogenous expression, poor antibody availability, or challenging cellular localization require specialized assay strategies. We develop sensitive detection formats, enrichment protocols, and alternative readouts to extract reliable activity data even from technically demanding targets.
Cell Line Selection Based on Target and E3 Expression PROTAC activity is strongly influenced by target expression level, E3 ligase availability, and cellular uptake. Leveraging our custom protein expression and purification capabilities, we help clients select or engineer appropriate cell models that reflect target biology and enable meaningful activity measurement.
Assay Optimization for Limited Compound Availability Early-stage PROTACs are often available in small quantities. We optimize assay miniaturization, detection sensitivity, and experimental design to generate high-quality activity data with minimal compound consumption, ensuring that material constraints do not compromise decision-making.
Orthogonal Validation for High-Confidence Decisions Critical decisions in PROTAC optimization require confidence that activity data reflect true degradation. We implement orthogonal validation strategies using independent detection methods, genetic controls, and chemical probes to confirm that observed activity is specific, reproducible, and mechanistically sound.

Advantages

Why PROTAC Activity Assay Is Essential for Degrader Development?

Quantify Degradation with Pharmacological Precision

PROTAC activity assays provide DC₅₀, D_max, and kinetic parameters that describe degrader behavior with the same rigor as IC₅₀ values for inhibitors. This precision enables objective candidate comparison and informed prioritization.

Accelerate Lead Optimization Decisions

With reliable activity data, medicinal chemistry teams can focus optimization efforts on structural elements that genuinely improve degradation performance rather than pursuing changes that only affect binding or physicochemical properties.

Validate Mechanism and Rule Out False Positives

Not all compounds that reduce target levels operate through PROTAC-mediated degradation. Activity assays with mechanistic verification distinguish true degraders from transcriptional suppressors, translational inhibitors, and compounds causing indirect target loss.

Connect Activity Data with Molecular Design

By systematically varying linker composition, E3 ligase recruiter, and target ligand while measuring activity, researchers establish structure-degradation relationships that directly inform the next round of molecular design and synthesis.

Workflow

Our PROTAC Activity Assay Workflow

01

Project Requirement and Target Biology Review

We discuss the target protein, E3 ligase system, PROTAC structural features, desired activity parameters, available cell models, and prior data to define the most informative assay strategy and readout combination.

02

Compound, Control, and Cell Model Selection

Our team identifies appropriate positive and negative controls, including inactive analogs, parental compounds, and vehicle controls. Cell lines are selected or validated for target and E3 ligase expression relevant to the client's research context.

03

Assay Format Design and Detection Method Optimization

Based on target abundance, antibody availability, throughput needs, and compound quantity, we design the optimal assay format and detection platform. Method parameters including treatment time, dose range, and sampling intervals are optimized for robust data generation.

04

Dose-Response and Time-Course Activity Testing

PROTAC candidates are tested across carefully designed concentration ranges and time points to capture DC₅₀, D_max, degradation onset, hook-effect behavior, and recovery dynamics. Multiple replicates ensure statistical reliability.

05

Mechanistic Confirmation and Orthogonal Validation

Observed target loss is confirmed as proteasome-dependent degradation through inhibitor controls, ubiquitination assessment, and orthogonal detection methods. This step ensures that activity data reflect genuine PROTAC mechanism rather than assay artifacts.

06

Data Analysis, Candidate Ranking, and Optimization Guidance

BOC Sciences delivers a structured report summarizing all activity parameters, comparative candidate ranking, mechanistic conclusions, and practical recommendations for linker, E3 ligase, or warhead optimization informed by the activity dataset.

Advance Your PROTAC Program with Precise Activity Data

Partner with BOC Sciences to connect degradation activity, molecular mechanism, and rational degrader design.

Talk to Experts

Why Us

Why Choose BOC Sciences for PROTAC Activity Assay?

PROTAC-Specific Assay Development Experience

Our scientists understand that PROTACs are not conventional inhibitors. We design assays that capture catalytic degradation, ternary complex dynamics, and hook-effect behavior rather than simply measuring target binding or static endpoint inhibition.

Integrated Binding, Degradation, and Functional Readouts

We connect binding affinity, degradation activity, ternary complex behavior, ubiquitination verification, and functional pathway analysis into a unified dataset that reveals how each molecular parameter contributes to overall PROTAC performance.

Flexible Platforms for Diverse Targets and Cell Models

Our multi-platform infrastructure supports activity assay development for a broad spectrum of target classes, E3 ligase systems, and cellular contexts. We adapt detection methods, assay formats, and experimental conditions to match each project's specific biology.

Data Interpretation Beyond Single-Point Activity Results

Rather than reporting isolated numbers, we interpret DC₅₀, D_max, kinetics, and mechanistic data in the context of each client's molecular structure, optimization goals, and research stage to provide actionable guidance.

Seamless Connection with PROTAC Design and Optimization Services

Activity assay data flows directly into our PROTAC design services, linker design and optimization services, and synthesis workflows, creating an integrated development pathway where activity insights inform molecular redesign without communication gaps.

Reliable Support for Pharmaceutical and Biotech Research Teams

We support discovery teams at pharmaceutical companies, biotechnology firms, and academic research institutions with flexible engagement models, transparent reporting, and scientific consultation throughout the activity assay process.

Applications

Applications of PROTAC Activity Assay Services

PROTAC Hit Identification

Confirm that screened compounds genuinely induce target degradation rather than binding alone. Activity assays at the hit validation stage eliminate false positives and establish which compounds merit progression to lead optimization.

Degradation Potency and Efficacy Comparison

Rank PROTAC candidates by DC₅₀, D_max, and degradation efficiency across matched conditions. Comparative activity data provides an objective basis for prioritizing analogs with the most favorable degradation profiles.

Linker and E3 Ligase Recruiter Optimization

Determine how linker length, polarity, flexibility, and E3 ligase identity influence degradation activity. Activity data guide structural decisions on which combinations deliver optimal potency, efficacy, and cellular behavior.

Target Degradation Mechanism Verification

Confirm that target loss occurs through the expected ubiquitin-proteasome pathway rather than alternative mechanisms. Mechanistic verification strengthens scientific confidence and supports publication-quality data requirements.

Degrader Selectivity and Functional Response Assessment

Measure degradation activity against the target of interest alongside related family members or pathway proteins. Combined with PROTAC selectivity evaluation services, this approach reveals whether potency comes with acceptable selectivity margins.

Integrated Support for PROTAC Discovery Programs

Activity assays serve as the central data hub connecting target validation, medicinal chemistry, and mechanistic biology. BOC Sciences integrates activity data with solubility and stability profiling and structural analysis to support comprehensive PROTAC discovery programs.

Case Study

Case Studies: PROTAC Activity Assay for Lead Optimization

Project Background

A US-based biotechnology company was advancing a series of CRBN-recruiting BRD4 PROTACs for oncology transcriptional program modulation. The chemistry team had synthesized 18 analogs with systematic variations in linker length (PEG2 to PEG6), linker polarity, and CRBN ligand attachment position. While all analogs showed BRD4 binding in biochemical assays, the team lacked degradation activity data to determine which structures actually induced efficient target removal in cells. They needed a systematic activity assay to rank candidates by degradation potency and efficacy.

Technical Challenges

BRD4 exists as multiple isoforms (BRD4-long and BRD4-short) with different cellular functions and expression patterns. The client needed activity data that distinguished isoform-selective degradation from pan-BRD4 removal. Additionally, BRD4 is a high-abundance chromatin-associated protein, requiring sensitive detection to accurately measure partial degradation. The 18 analogs varied in solubility, making standard assay conditions potentially misleading for hydrophobic variants.

BOC Sciences Solutions

Isoform-Resolved Degradation Quantification: We developed a capillary immunoassay protocol that simultaneously quantified BRD4-long and BRD4-short protein levels across all 18 analogs at 6, 12, and 24 h time points, using pan-BRD4 and isoform-selective antibodies to resolve degradation selectivity.
Hook-Effect and Concentration-Response Profiling: Each analog was tested across a 10,000-fold concentration range to capture full concentration-response curves, identify hook-effect behavior, and accurately determine DC₅₀ and D_max values for both BRD4 isoforms.
Degradation Kinetics and Recovery Analysis: Time-course profiling from 1 h to 48 h revealed that longer PEG linkers accelerated degradation onset but also accelerated target recovery after washout, while shorter linkers produced slower but more sustained degradation. Recovery assays after compound removal were performed to assess re-synthesis rates.

Project Outcomes

BOC Sciences identified a PEG4-linked lead with strong BRD4-long degradation potency, high D_max, and a favorable isoform selectivity window, enabling the client to prioritize this candidate and guide the next analog generation toward medium-length PEG linkers.

Project Background

A European pharmaceutical research group was developing a VHL-recruiting STAT3 PROTAC for solid tumor signaling pathway studies. Initial analogs showed moderate STAT3 binding affinity but weak cellular degradation activity. The team hypothesized that poor ternary complex formation between STAT3, the PROTAC, and VHL E3 ligase was limiting degradation efficiency. They needed activity assays that specifically evaluated ternary complex contribution to guide structural modifications.

Technical Challenges

STAT3 functions as a transcription factor with both cytoplasmic and nuclear localization, creating uncertainty about which cellular compartment was most relevant for productive ternary complex formation. The client's original analogs contained rigid alkyl linkers that may have constrained the spatial geometry needed to bridge STAT3 and VHL simultaneously. Distinguishing whether weak degradation reflected poor target engagement, inadequate ternary complex stability, or suboptimal cellular uptake required carefully designed activity assays.

BOC Sciences Solutions

Ternary Complex-Focused Activity Assay: We designed degradation assays that measured STAT3 protein levels following PROTAC treatment in cells with endogenous VHL expression versus VHL-knockdown conditions. The differential activity between these backgrounds directly quantified the VHL-dependent degradation component attributable to productive ternary complex formation.
Linker Flexibility and Cooperativity Screening: Eight new analogs with systematically varied linker flexibility (rigid alkyl, semi-rigid, flexible PEG-alkyl hybrid) were synthesized and evaluated for STAT3 degradation activity, DC₅₀, D_max, and hook-effect behavior to identify the linker architecture most conducive to productive STAT3-VHL bridging.
Subcellular Degradation Localization Analysis: Using immunofluorescence-based activity assays, we tracked STAT3 degradation kinetics separately in cytoplasmic and nuclear compartments to determine where productive ternary complex formation was occurring and whether linker modifications could enhance activity in the preferred compartment.

Project Outcomes

BOC Sciences confirmed that productive STAT3-VHL ternary complex formation was the main activity driver and identified a semi-rigid linker analog that substantially improved STAT3 degradation potency, degradation depth, and cytoplasmic target removal for follow-up pathway studies.

Frequently Asked Questions (FAQ)

Frequently Asked Questions

Still have questions?

Contact Us

What key readouts define PROTAC activity?

PROTAC activity assays should evaluate more than whether the target protein level decreases. Key readouts include DC50, Dmax, degradation kinetics, hook effect, target protein recovery, target engagement, ternary complex formation, ubiquitination dependence, proteasome dependence, and cellular functional response. These data help discovery teams determine whether a compound acts through true targeted protein degradation or causes indirect protein changes. BOC Sciences designs customized assay strategies based on target biology, E3 ligase choice, compound stage, and cell model requirements to generate decision-ready activity profiles.

Why are DC50 and Dmax both important?

DC50 reflects the concentration required to achieve 50% target protein degradation, while Dmax describes the maximum degradation level reached under defined assay conditions. A PROTAC may show a low DC50 but only partial degradation, or it may require a higher concentration to achieve deep and sustained target depletion. Evaluating both parameters helps avoid overinterpreting potency alone. BOC Sciences often combines DC50, Dmax, time-course degradation, recovery behavior, and cellular response data to distinguish strong degraders from partial degraders or compounds with unclear mechanisms.

How can PROTAC ternary complex dependence be confirmed?

Ternary complex dependence can be assessed by combining target binding, E3 ligase engagement, concentration-response profiling, cooperativity analysis, E3-dependence controls, ubiquitination assays, and proteasome-dependence studies. If a PROTAC binds the target and E3 ligase but shows weak cellular degradation, the limitation may involve poor ternary complex geometry, unfavorable linker orientation, inadequate cellular exposure, or insufficient productive complex stability. BOC Sciences integrates ternary complex assays with cell-based degradation and mechanism validation to help clients identify the activity-limiting factor and guide linker or attachment-site optimization.

When should hook effect be evaluated?

Hook effect should be evaluated when degradation decreases at high PROTAC concentrations or when the concentration-response curve shows a bell-shaped, non-linear, or unexpected plateau pattern. This phenomenon may occur when excess PROTAC molecules separately occupy the target protein and E3 ligase, reducing productive ternary complex formation. Ignoring hook effect can lead to inappropriate concentration selection and inaccurate candidate ranking. BOC Sciences uses broad concentration gradients, time-course testing, and ternary complex interpretation to identify the optimal activity window and support more accurate downstream assay design.

How should a PROTAC activity platform be selected?

The activity assay platform should be selected according to target protein abundance, antibody availability, cell model relevance, throughput needs, compound quantity, and the project stage. Western blot and capillary immunoassay are useful for direct target protein quantification, high-content imaging supports localization and cell-to-cell heterogeneity analysis, flow cytometry enables single-cell profiling, and mass spectrometry-assisted methods can support difficult targets or limited antibody options. BOC Sciences helps clients build fit-for-purpose assay combinations that reduce interpretation bias and connect degradation activity with mechanism and cellular function.

Testimonials

Client Testimonials on PROTAC Activity Assay

Decision-Ready Degradation Activity Data for Lead Selection

"We had twelve BRD4 PROTAC analogs with nearly identical binding data but no idea which ones actually degraded the target. BOC Sciences delivered DC₅₀ and D_max values across all compounds within three weeks, and the activity ranking completely changed our lead prioritization. The PEG4 analog we selected based on their data is now the cornerstone of our program."

— Dr. Brennan, Head of Targeted Degradation Biology at a US Biotech Firm

Insightful Interpretation of DC₅₀, D_max, and Hook Effect

"The activity data we received was not just numbers in a spreadsheet. The BOC Sciences team walked us through the hook-effect behavior in our CRBN-recruiting series, explained why the high-concentration drop-off was happening, and suggested linker modifications that would stabilize the ternary complex. That interpretation was invaluable."

— Dr. Okafor, Principal Scientist at a European Pharmaceutical Research Group

Valuable Support for Ternary Complex and Mechanism Validation

"Our VHL-recruiting PROTAC showed strange activity profiles that we could not explain. BOC Sciences designed a ternary complex-focused assay comparing VHL-proficient and VHL-deficient backgrounds, which immediately clarified that our weak activity was due to poor complex formation rather than cell permeability. We re-engineered the linker based on their guidance and saw a dramatic improvement."

— Ms. Lindqvist, Project Manager at a Nordic Oncology Research Organization

Practical Guidance for PROTAC Analog Optimization

"Beyond the excellent activity data, what set BOC Sciences apart was their ability to connect the assay results back to our medicinal chemistry efforts. They identified which structural changes correlated with improved degradation and which had no effect, allowing our team to focus synthetic resources on the most productive modifications."

— Dr. Patel, Medicinal Chemistry Director at a UK-Based Biotechnology Company